

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Open Session

Date:	11/5/2025
Present:	Peter Halfmann, Matt Reynolds, Donna Neumann, Andrea Ladd, Warren Rose, Gregory Gauthier, Ryan Stoffel, Garret Suen, Joel Malak, Clint Morgan, Sabine Pellett, Steve Garvis
Consultants:	Tony Mcgrath, Lissa Koop, Darren Berger, Christina Pier, Carrie Ensrud, John Cejka, Quin Koehl
OBS:	Tony Mcgrath, TJ Whyte, David Dyer, Karen Demick, Christina Pier, Andrea Ladd, Louise Meske, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Kathy Krasny, Quin Koehl
Guests:	Sarah Johnson, CALS
Call to order:	The meeting was called to order by Garret Suen, at Zoom at 1:31 pm
Announcements:	The IBC meeting is open to the public.
Review of Minutes:	A motion to approve the open session minutes of the following IBC meetings was Unanimously adopted. Institutional Biosafety Committee meeting on (10/1/2025) Absent: Warren Rose, Greg Gauthier Abstain: Matt Reynolds
Approval of Registered Protocols:	A motion to approve registered protocols was Unanimously adopted Absent: Warren Rose, Greg Gauthier

Other business - open session

- **Agenda Items - Documents For Open Session:**
- **List of Registered Protocols_080625-090325_AM.xlsx**

- **List of Registered Protocols_080625-090325_GP.xlsx**
- **IBC Human Subjects training 2025_v2-1.pptx**

Review of research protocols - open session

 **B00001227**

 **B00001230**

 **B00001231**

 **B00001233**

Review of research amendments - open session

 **B00000302-AM009**

 **B00000339-AM014**

 **B00000399-AM007**

 **B00000440-AM027**

 **B00000506-AM016**

 **B00000575-AM007**

 **B00000762-AM008**

 **B00000821-AM014**

 **B00001167-AM002**

 **B00001171-AM001**

Announcements

null

The meeting adjourned 2:43 pm

- **Bio Protocol Number: B00001227**

PI Name: [REDACTED]

Protocol Title: Mechanisms of Drug Tolerance (Persistence) and Resistance in Bacteria and Eukaryotic Cells

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Greg Gauthier

Biosafety Level: BSL2; ABSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood, Other - bioBubble (performance tested by the BSC Certification Program); Biological safety cabinet (BSC), Chemical fume hood, Ventilated HEPA-filtered housing or rack system, Other - Animal Transfer Stations (ATS) present in all mouse rooms; downdraft tables available in some procedure rooms.; Biological safety cabinet (BSC), Chemical fume hood, Ventilated HEPA-filtered housing or rack system;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing

information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This is a new protocol from a laboratory that studies drug resistance in bacteria and cancer cells. Non-pathogenic E. coli and established cancer cell lines are used as the primary model systems. The IBC requests more detail about strains and compounds used in the experiments. The IBC approved PI status contingent on providing a signed PI status form.

- **Bio Protocol Number: B00001230**

PI Name: [REDACTED]

Protocol Title: Studying glial roles in aging and neurodegenerative disease using zebrafish models

Motion: IBC approved protocol

Motion Made By: Steve Garvis

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Greg Gauthier

Biosafety Level: ABSL1; BSL1; ABSL1; BSL2; BSL2; ABSL2, BSL2; ABSL2, BSL2; ABSL2, BSL2; ABSL2; BSL2; ABSL2, BSL2; ABSL2, BSL2; ABSL1; BSL1;

Containment Equipment: Not applicable; Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from

the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4) (III-D-4-a) (III-D-4-b); (III-F-1);

Summary of IBC Review: This is a new protocol from a laboratory that studies microglia during normal aging and disease using zebrafish as a model system.

Biosafety is adequately addressed.

- **Bio Protocol Number: B00001231**

PI Name: Marc Chevette

Protocol Title: Mining Bacterial Genomes for Antibacterial and Antifungal Natural Products

Motion: IBC tabled the protocol

Motion Made By:

Motion Seconded By:

Committee Action: Other

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Not applicable; Chemical fume hood; Not applicable;

Committee Review: There was insufficient information for risk assessment. The protocol was tabled.

Facilities: null

Required Institutional Training: null

Lab-specific Training and Expertise: null

PPE, Controls, and Practices: null

NIH Guidelines Requirements: null

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E); (III-E); (III-F-8); (III-F-8); (III-F-4) (III-F-5);

Summary of IBC Review: This is a new protocol for a laboratory that studies the ecological roles of biosynthetic gene clusters and antimicrobial products. The protocol was tabled due to a lack of experimental detail in the research description.

- **Bio Protocol Number: B00001233**

PI Name: Sanna Herwald

Protocol Title: Analysis of Percutaneous Drainage

Motion: IBC approved with contingencies

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; Not applicable (non-laboratory area);

Containment Equipment: Biological safety cabinet (BSC); Other - Standard BSL2 laboratory benches. ; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines:

Summary of IBC Review: This is new protocol for a laboratory that studies the effectiveness of treatments to thin abscess fluids to prevent clogging of drain tubing. The IBC discussed containment for analysis of human samples using a rheometer.

- **Bio Protocol Number: B00000302-AM009**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 009 for Biosafety Protocol for the Study of Bovine related Pathogens in the Doefer laboratory

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; Not applicable (non-laboratory area); BSL2;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: null

NIH Guidelines:

Summary of IBC Review: The laboratory studies bovine-related pathogens. In this amendment, a study to test methods for cleaning blenders after preparation of veterinary blended diets is proposed. The IBC noted that smoke tests demonstrated that operation of the blender in the BSC did not disrupt containment. The IBC requests additional details for testing and disposal procedures.

- **Bio Protocol Number: B00000339-AM014**

PI Name: Loren Denlinger

Protocol Title: Amendment/Renewal 014 for Functional responses of eosinophils, neutrophils, monocytes, macrophages, stellate cells, hepatocytes, or epithelial cells in allergic, pulmonary, or hepatic disorders.

Motion: IBC approved protocol

Motion Made By: Donna Neumann

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; Other - Clinical; BSL2; BSL2; BSL2; BSL2; Not applicable (non-

laboratory area); BSL2; BSL2;

Containment Equipment: Chemical fume hood, Other - Single Pass Ventilation; Not applicable; Other - Portable Aerosol Therapy Containment Enclosure, Single Pass Ventilation; Other - Single Pass Ventilation; Biological safety cabinet (BSC), Other - Single Pass Ventilation; Other - Single Pass Ventilation; Not applicable; Other - Sink; Other - Single Pass Ventilation; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Other - Single Pass Ventilation; Other - Portable Aerosol Therapy Containment Enclosure; Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-E-1); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies mechanisms and risk factors for acute airway symptoms in healthy, allergic, and asthmatic people. In this amendment, transfer of work performed under a collaborator's protocol is proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000399-AM007**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 007 for Vocal fold biology and tissue repair

Motion: IBC approved protocol

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; ABSL2; ABSL2; ABSL2; BSL2; ABSL2; ABSL2; BSL2; ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC);

Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4-b); (III-E-3); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies scarred vocal fold and voice impairment using various cell culture and animal models. In this amendment, experiments implanting engineered human fold mucosal tissue in swine are proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000440-AM027**

PI Name: Chris Bartley

Protocol Title: Amendment/Renewal 027 for Waisman Biomanufacturing Biosafety Protocol

Motion: IBC approved protocol

Motion Made By: Gregory Gauthier

Motion Seconded By: Sabine Pellett

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Abstain: Peter Halfmann

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

BSL2; BSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2; Not

applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet

(BSC); Biological safety cabinet (BSC), Chemical fume hood; Not applicable;

Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC);

Other - Decontamination Autoclave; Not applicable; Biological safety cabinet (BSC);

Not applicable; Chemical fume hood; Biological safety cabinet (BSC); Chemical

fume hood; Biological safety cabinet (BSC); Not applicable; Biological safety

cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC);

Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety

cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents

involved in the proposed work. The IBC considered agent characteristics including

but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-6); (III-D-2-a); (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E); (III-E-1); (III-F-8);

Summary of IBC Review: This is an umbrella protocol is for Waisman

Biomanufacturing, a cleanroom facility providing manufacturing and testing

services to academic researchers and industry partners for a range of biopharmaceutical products. In this amendment, activities with *Listeria monocytogenes* are proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000506-AM016**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 016 for Biology of Papillomaviruses

Motion: IBC approved with contingencies

Motion Made By: Donna Neumann

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2; ABSL1; ABSL1; BSL2; BSL2; ABSL2; ABSL2; BSL1; ABSL1; ABSL2; BSL1; ABSL2; ABSL2; ABSL2; ABSL2; ABSL2; ABSL2; BSL1; BSL1; ABSL2; BSL1; BSL1; BSL1; ABSL1; ABSL2; BSL1; BSL2;

Containment Equipment: Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC) - The BSC is vented to the outside of the building via the building's exhaust system; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4-b); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8);

Summary of IBC Review: The laboratory studies human and mouse papillomaviruses. In this amendment, vaccine studies using Staphylococcus epidermidis are proposed. The IBC recommends that Occupational Medicine be consulted for post-exposure follow-up rather than a personal provider due to their experience with laboratory incidents, although it was noted that under workers' compensation an employee may seek medical care from the provider of their choice.

- **Bio Protocol Number: B00000575-AM007**

PI Name: Samuel Butcher

Protocol Title: Amendment/Renewal 007 for RNA and protein production and purification for biochemical studies

Motion: IBC approved protocol

Motion Made By: Peter Halfmann

Motion Seconded By: Matt Reynolds

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Warren Rose, Greg Gauthier

Biosafety Level: BSL1; BSL1; BSL1; BSL1; BSL2;

Containment Equipment: Chemical fume hood; Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative

controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-E); (III-E-1); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: The laboratory studies the structure and function of RNAs that regulate gene expression. In this amendment, use of cell lines to study RNA splicing of reporter genes is proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000762-AM008**

PI Name: Elizabeth Wright

Protocol Title: Amendment/Renewal 008 for Structural studies of host-pathogen relationships by cryo-EM, light microscopy, and molecular approaches

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Abstain: Peter Halfmann, Steve Garvis

Biosafety Level: BSL2; Not applicable (non-laboratory area); BSL2; BSL1; BSL2; BSL2; BSL1; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL1; ABSL1, BSL1; BSL2; BSL2; ABSL1, BSL1; BSL2; BSL2; BSL2; BSL2; BSL2; BSL1; BSL2; BSL1; Not applicable (non-laboratory area); Not applicable (non-laboratory area); BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Other - Only small quantities of sample will enter this space, remaining unfixed sample will be moved back to B1106G; Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4-a) (III-D-4-b); (III-D-4) (III-D-4-a) (III-D-4-b); (III-D-2-a); (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: The laboratory uses cryo-electron microscopy and molecular approaches to study the 3D structures of cells, microbes, and macromolecular complexes. In this amendment, experiments with enterovirus and *Pseudomonas aeruginosa* strains are proposed. The IBC requests more detail about transport of materials during live cell imaging.

- **Bio Protocol Number: B00000821-AM014**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 014 for *Salmonella* pathogenesis

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Steve Garvis

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2; Not applicable (non-laboratory area); ABSL2; ABSL2; BSL2; ABSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL1;

Containment Equipment: Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a)(III-D-1-b); (III-E); (III-E); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies how bacterial pathogens colonize the intestine and cause illness. In this amendment, experiments with recombinant *Cronobacter sakazakii* are proposed. Requested revisions include providing more detail about cell source and modification of spill procedures.

- **Bio Protocol Number: B00001167-AM002**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 002 for Cellular and Molecular Mechanisms of Stem Cell Aging

Motion: IBC approved protocol

Motion Made By: Steve Garvis

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL1, BSL1; BSL2; ABSL1; BSL1; BSL1; BSL1; ABSL1, BSL1; BSL2; BSL1; BSL2; BSL1; BSL1;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable;

Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4-b); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies how aging affects the body using transgenic mice and cell culture models. In this amendment, experiments with human autopsy samples are proposed. Biosafety is adequately addressed.

- **Bio Protocol Number: B00001171-AM001**

PI Name: Bryan Bednarz

Protocol Title: Amendment/Renewal 001 for Radiological Engineering and Design (RED) Laboratory

Motion: IBC approved with contingencies

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL1, BSL2; BSL2;

Containment Equipment: Not applicable, Other - -80°C biological sample freezer, freezer is shared-use; Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents

involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines:

Summary of IBC Review: This is an umbrella protocol for the Advanced Imaging and Dosimetry Core facility, which prepares and images murine tissue samples for detection of radiopharmaceuticals. In this amendment, use of a scroll saw during isolation of frozen tumor samples is proposed. The IBC requests clarification regarding transport of materials.

Kathy Krasny presented training for the IBC on human clinical trials in Bio-ARROW.

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Closed Session

Date: 11/5/2025

Present: Peter Halfmann, Matt Reynolds, Donna Neumann, Andrea Ladd, Warren Rose, Gregory Gauthier, Ryan Stoffel, Garret Suen, Joel Malak, Clint Morgan, Sabine Pellett, Steve Garvis

Consultants: Tony Mcgrath, Lissa Koop, Darren Berger, Christina Pier, Carrie Ensrud, John Cejka, Quin Koehl

OBS: Tony Mcgrath, TJ Whyte, David Dyer, Karen Demick, Christina Pier, Andrea Ladd, Louise Meske, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Kathy Krasny, Quin Koehl

Guests: Sarah Johnson, CALS David Aufhauser, PI Vishal Chanana, Aufhauser lab Chris Saddler, Aufhauser lab

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:31 pm

Announcements: The IBC meeting is closed to the public.

Review of Minutes: A motion to approve the closed session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (10/1/2025)

Absent: Warren Rose, Greg Gauthier

Other business - closed session

- **Agenda Items - Documents For Closed Session:**

Review of research protocols - closed session

☐ B00001232

☐ B00001236

Review of research amendments - closed session

❓ **B00000577-AM006**

❓ **B00001027-AM003**

Announcements

null

The meeting adjourned 2:43 pm

- **Bio Protocol Number: B00001232**

PI Name: Vaishalee Kenkre

Protocol Title: UW25097: A Phase 1b/2 Multicenter, Open-label, Study of [REDACTED]
[REDACTED] CAR-T Cell Therapy in Adult

Participants with B-cell Non-Hodgkin Lymphoma

Motion: IBC approved protocol

Motion Made By: Joel Malak

Motion Seconded By: Donna Neumann

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Absent: Greg Gauthier, Warren Rose

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL1;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC) - 2

Biological safety cabinet (BSC) that are certified bi-annually.; Not applicable;

Biological safety cabinet (BSC), Chemical fume hood - BSC is SterilGARD Baker Company; Fume hood is technically in Immunology, but that is also B4/220- the processing area does have access to it if needed ;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities

or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-C-1);

Summary of IBC Review: This is a new protocol for a phase 1b/2 clinical trial for an autologous CAR-T cell therapy to treat non-Hodgkin lymphoma in adults. Biosafety is adequately addressed.

- **Bio Protocol Number: B00001236**

PI Name: David Aufhauser

Protocol Title: GPK-KF-101 EXPAND

Motion: IBC approved with contingencies

Motion Made By: Joel Malak

Motion Seconded By: Peter Halfmann

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Absent: Greg Gauthier

Biosafety Level: Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in

the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-C-1);

Summary of IBC Review: This is a new protocol for a first in kind clinical trial involving transplantation of kidneys from genetically engineered pigs into adult humans with end state renal disease who lack timely access to human organs. The kidney is sourced from designated pathogen free pigs. The IBC discussed spill procedures and determined them to be adequate. Some minor administrative changes are requested.

- **Bio Protocol Number: B00000577-AM006**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 006 for Epigenetic's in mammalian development and disease

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Sabine Pellett

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Absent: Greg Gauthier

Biosafety Level: ABSL2; ABSL1; BSL1; ABSL1, ABSL2; ABSL1; BSL1; BSL2; BSL2; ABSL1; BSL2; BSL1;

Containment Equipment: Biological safety cabinet (BSC); Ventilated HEPA-filtered housing or rack system; Chemical fume hood; Not applicable; Other - downdraft table; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and

activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-3); (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: The laboratory studies Rett syndrome using mouse models and human stem cells. In this renewal, no changes to research are proposed. The IBC requests revisions for experiments involving toxin to better address reconstitution and emergency procedures.

- **Bio Protocol Number: B00001027-AM003**

PI Name: Christopher Saddler

Protocol Title: Amendment/Renewal 003 for [REDACTED] Vaccine For The Prevention of Cytomegalovirus (CMV) in Healthy Adults (16 - 40 Years of Age)

Motion: IBC approved protocol

Motion Made By: Garret Suen

Motion Seconded By: Joel Malak

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Absent: Greg Gauthier

Biosafety Level: BSL2; BSL2; Not applicable (non-laboratory area); Not applicable (non-laboratory area); BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-C-1);

Summary of IBC Review: This protocol is for a clinical trial testing an mRNA-based vaccine. In this amendment, a change in PI is proposed. No changes to study design or procedures are proposed. Biosafety is adequately addressed. The IBC approved the PI change and the PI status for the new PI.

Andrea Ladd gave the IBC incident report.